TetraKit

Next Generation Theranostics

circles design
molecules

TetraKit: Next Generation Theranostics

Targeted radionuclide therapy is an emerging field that has shown great promise in the treatment of late-stage metastatic cancer. Theranostics combines radionuclide therapy with diagnosis by nuclear imaging. In theranostics, cancer-targeting molecules, known as radiopharmaceuticals, carry radioactive atoms specifically to tumors. Depending on which type of radiation is chosen, physicians can either diagnose the severity and spread of the cancer or treat it by selectively destroying the cancerous tissue. TetraKit is a new, click chemistry based radiochemical platform, which allows for labeling of virtually any cancer-targeting molecule with any radionuclide pair for theranostics. TetraKit Technologies focuses its development program on fluorine-18 and astatine-211 as this pair is the best suited radionuclide pair for PET imaging and targeted alpha-radionuclide therapy. Alpha-therapy has attracted wide interest in current oncology as it succeeded where conventional therapies failed. TetraKit will develop the next generation of theranostic radiopharmaceuticals, which will improve patient care and disease outcomes.

Logo transparent

Latest news

from TetraKit Technologies

May 20, 2023

ISRS

We are delighted to announce that our distinguished Chief Scientific Officer, Dr. Matthias Herth, will attend the 25th International Society for Radiopharmaceutical Sciences (ISRS) conference in beautiful Hawaii.

The ISRS conference, renowned for fostering innovation and collaboration, is an ideal platform for presenting our pioneering work and engaging with fellow industry thought leaders. We eagerly anticipate the exchange of ideas that will occur and the partnerships that could potentially evolve from this assembly of bright minds.

Here’s to pushing boundaries toward a brighter, healthier future.

Read more

May 10, 2023

BioEquity

Our COO, Umberto Maria Battisti, will attend the 23rd annual @BioEquity conference in Dublin, Ireland! Umberto’s participation in BioEquity Europe 2023 highlights our commitment to innovation and growth. During the conference, he will seek new partnerships, discuss the latest advancements in biotechnology, and share insights into our company’s strategy for sustained success. We invite you to celebrate Umberto’s journey to Dublin with us, and stay tuned for updates on his experience at this prestigious event. Together, let’s pave the way for a brighter future in biotech! 

Read more

May 8, 2023

Noar 2

We’re excited to announce that TetraKit will attend the 2nd Annual Global Meeting COST NOAR Astatine in Coimbra, Portugal, from May 9-11, 2023! This event will bring together academics and industry experts to discuss the latest developments in targeted alpha therapy using astatine-211. Our CEO, Andreas Ingemann Jensen, and CSO, Matthias Herth, represent TetraKit at this global conference. They look forward to engaging in productive conversations, exchanging ideas, and learning from the invited speakers. We’re thrilled to network with fellow professionals and contribute to the progress in this innovative field.

We’ll see you in Coimbra!
#NOAR2023 #TargetedAlphaTherapy #Astatine211 #TetraKit #Coimbra #Portugal #Networking #Innovation #Research

Read more

Message from the CEO

Andreas Jensen, PhD

Andreas Jensen, PhD

Chief Executive Officer

Message from the CEO

“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”

Message from the CSO

Matthias Herth, PhD

Matthias Herth, PhD

Chief Scientific Officer

Message from the CSO

“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”